MiR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling

Blood

Volumn 121, Issue 15, 2013, Pages 2875-2881

  Bhagat, Tushar D ^a   Zhou, Li ^a   Sokol, Lubomir ^b   Kessel, Rachel ^a   Caceres, Gisela ^b   Gundabolu, Krishna ^a   Tamari, Roni ^a   Gordon, Shanisha ^a   Mantzaris, Ioannis ^a   Jodlowski, Tomasz ^a   Yu, Yiting ^a   Jing, Xiaohong ^a   Polineni, Rahul ^a   Bhatia, Kavi ^a   Pellagatti, Andrea ^c   Boultwood, Jacqueline ^c   Kambhampati, Suman ^d   Steidl, Ulrich ^a   Stein, Cy ^a   Ju, Wenjun ^e   Liu, Gang ^f   Kenny, Paraic ^a   List, Alan ^b   Bitzer, Markus ^a,e   Verma, Amit ^a   more..

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 21; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; GREEN FLUORESCENT PROTEIN; MICRORNA; MIRN21 MICRORNA, HUMAN; SMAD7 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1;

3' UNTRANSLATED REGION; ADULT; AGED; ANEMIA; ANIMAL CELL; ARTICLE; BINDING SITE; BONE MARROW DEPRESSION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DYSPLASIA; ERYTHROID CELL; FEMALE; GENE; HEMATOCRIT; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BONE MARROW CELL; CELL CULTURE; CELL LINE; CELL STRAIN K 562; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; VERY ELDERLY;

3' UNTRANSLATED REGIONS; AGED; AGED, 80 AND OVER; ANIMALS; BINDING SITES; BONE MARROW CELLS; CELL LINE; CELLS, CULTURED; FEMALE; GENE EXPRESSION; GREEN FLUORESCENT PROTEINS; HEMATOPOIESIS; HUMANS; K562 CELLS; MALE; MICE; MICE, TRANSGENIC; MICRORNAS; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; SIGNAL TRANSDUCTION; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

MLCS; MLOWN;

EID: 84879149544     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-397067     Document Type: Article

References (34)

1. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999;340(21):1649- 1660. (Pubitemid 29249435)
2. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 1998;83(4):358-368. (Pubitemid 28217858)
3. Greenberg PL. Biologic nature of the myelodysplastic syndromes. Acta Haematol. 1987;78(Suppl 1):94-99. (Pubitemid 18074562)
4. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. (Pubitemid 27132124)
5. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86(1):268-276.
6. Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res. 1998;22(12):1123-1136. (Pubitemid 29002986)
7. Westwood NB, Mufti GJ. Apoptosis in the myelodysplastic syndromes. Curr Hematol Rep. 2003;2(3):186-192.
8. Ohshima K, Karube K, Shimazaki K, et al. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis. Leuk Lymphoma. 2003;44(8):1339-1346. (Pubitemid 36764288)
9. Zorat F, Shetty V, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol. 2001;115(4):881-894. (Pubitemid 34042906)
10. Allampallam K, Shetty V, Mundle S, et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol. 2002;75(3):289-297. (Pubitemid 43014062)
11. Allampallam K, Shetty V, Hussaini S, et al. Measurement of mRNA expression for a variety of cytokines and its receptors in bone marrows of patients with myelodysplastic syndromes. Anticancer Res. 1999;19(6B):5323-5328. (Pubitemid 30103369)
12. Powers MP, Nishino H, Luo Y, et al. Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Arch Pathol Lab Med. 2007;131(12):1789-1793. (Pubitemid 350294578)
13. Akiyama T, Matsunaga T, Terui T, et al. Involvement of transforming growth factor-beta and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis. Leukemia. 2005;19(9):1558-1566. (Pubitemid 43090399)
14. Taketazu F, Miyagawa K, Ichijo H, et al. Decreased level of transforming growth factor-beta in blood lymphocytes of patients with aplastic anemia. Growth Factors. 1992;6(1):85-90.
15. Gyulai Z, Balog A, Borbe′nyi Z, et al. Genetic polymorphisms in patients with myelodysplastic syndrome. Acta Microbiol Immunol Hung. 2005;52(3-4):463-475. (Pubitemid 41804788)
16. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96(6):2240-2245.
17. Yoon SY, Li CY, Lloyd RV, et al. Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders. Int J Hematol. 2000;72(3):337-342.
18. Zhou L, McMahon C, Bhagat T, et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res. 2011;71(3):955-963.
19. Verma A, Deb DK, Sassano A, et al. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol. 2002;168(12):5984-5988. (Pubitemid 34620009)
20. Pellagatti A, Cazzola M, Giagounidis A, et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia. 2010;24(4):756-764.
21. Sokol L, Caceres G, Volinia S, et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol. 2011;153(1):24-32.
22. Bitzer M, Ju W, Jing X, et al. Quantitative analysis of miRNA expression in epithelial cells and tissues. Methods Mol Biol. 2012;820:55-70.
23. Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A. 1995;92(7):2572-2576.
24. Yu L, Hébert MC, Zhang YE. TGF-beta receptora-ctivated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 2002;21(14):3749-3759. (Pubitemid 34787048)
25. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 2010;207(8):1589-1597.
26. Verma A, Deb DK, Sassano A, et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J Biol Chem. 2002;277(10):7726-7735. (Pubitemid 34968219)
27. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704-714.
28. Zhou L, Nguyen AN, Sohal D, et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood. 2008;112(8):3434-3443.
29. Akhurst RJ. TGF beta signaling in health and disease. Nat Genet. 2004;36(8):790-792. (Pubitemid 39014092)
30. Tenesa A, Farrington SM, Prendergast JG, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet. 2008;40(5):631-637. (Pubitemid 351601219)
31. He W, Dorn DC, Erdjument-Bromage H, et al. Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell. 2006;125(5):929-941. (Pubitemid 43795187)
32. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-4395. (Pubitemid 351377805)
33. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
34. Iliopoulos D, Jaeger SA, Hirsch HA, et al. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010;39(4):493-506.